D. Boral Capital maintains ImmunityBio with a Buy and maintains a price forecast of $24
No, but now I have thanks to this post. Quite a run-up. Looks like insiders are looking to (quite understandably) offload some of their stakes thanks to this FDA move
The reason I posted this is to find out whether here at P123 we can check for companies where the analysts’ price target is a multiple of the current price. In July 2025 the average target price was $11.40 when it was trading at $2.70. The minimum forecast was $5.00 and the maximum was $30.00.
A hit or miss cohort by itself but you sure can. It can be greatly improved with a few common sense rules though.
IBRX today at $11.50, up from $6.50 when I posted this originally on Jan 20.
1 Like
Reached the target 